---

AssureR_x, LLC, is a personalized medicine company dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from a range of medical conditions. The company was founded in June 2006 to license and commercialize the industry-leading personalized medicine technology of Cincinnati Children’s Hospital and the Mayo Clinic.

QCA First Fund II joined with Blue Chip Validation Fund and Cincinnati Children's Hospital to provide seed round funding to launch the company and begin the process of commercializing the product.

---

Minimally Invasive Devices (MID) Inc. is a medical device company that develops novel disposable instruments which allow experienced surgeons to perform Minimally Invasive Surgery more quickly and safely, and also make it practical for less-experienced surgeons to perform the procedures as well. The initial product to be developed is Clear-Vu, an after-market attachable device to eliminate bothersome fogging and cleaning of the laparoscope during surgery.

Teaming with OTAF and NCT Ventures in Columbus, as well as a number of individual investors, the QCA First Fund II has provided equity funding to complete the development of the first product line.

---

Akebia Therapeutics is a start-up pharmaceutical company which has licensed select, high-quality drug development programs and assets from P&G. The company’s focus is on clinical development of novel compounds targeted for treatment of anemia and ischemia-related disorders. One of the primary ischemia-related products will be for treatment of peripheral artery disease (PAD).

QCA First Fund has joined a consortium of lenders including Triathalon Medical Ventures, Blue Chip Validation Fund, and Sigvion Capital to provide start-up capital to the company.

---

Xanthostat Diagnostics has developed and is pursuing FDA 510k approval for its initial product, which will measure bilirubin and hemoglobin concentrations in spinal fluid. This test will be an important advancement in the early and accurate diagnosis of subarachnoid hemorrhage. The company is using technology developed at and licensed from the University of Cincinnati.

A convertible loan was made to the company by the Fund to provide operating capital until the product receives FDA approval.

---

 
OnTrak POS Business Intelligence is subscription software used to order, track and manage semi-permanent and temporary signage in retail stores (POS).  OnTrak 's BI software lets distributors perform flexible analyses of massive amounts of POS data with the goal of improving effectiveness and decision making.

Individual members of QCA and CincyTech joined the Fund in a purchase of preferred equity in the company.

---